Urovant Sciences Ltd.   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: London United Kingdom (2016)
Status: Acquired by Sumitomo Dainippon (2019)

Organization Overview

First Clinical Trial
2018
NCT03492281
First Marketed Drug
2020
vibegron
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

UROVANT | Urovant Sciences | Urovant Sciences GmbH | UROVANT SCIENCES GMBH